Jejunoileal vs Gastric GIST in the Era of Imatinib.

Characteristics and Prognosis of Jejunoileal Gastrointestinal Stromal Tumors (GISTs) in the Era of Imatinib. A Comparative Retrospective Study With Gastric GISTs.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03923400

Enrollment

Registered

2019-04-22

Start date

2016-11-01

Completion date

2017-01-31

Last updated

2019-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disease-free Survival, Overall Survival, Recurrence

Keywords

GIST, small bowel, jejunum, ileum

Brief summary

Introduction: Gastrointestinal Stromal Tumors (GISTs) located in the jejunum or ileum (JI-GIST) are considered of worse prognosis compared to other locations. It has been suggested that this dogma should be revised. The aim of this study is to describe the characteristics of jejunoileal GISTs and its prognosis; and to compare them with gastric GISTs in the era of imatinib. Patients and methods: We retrospectively reviewed the clinical histories of all the patients diagnosed with GISTs between January 2000 and November 2016. Clinical and pathological data, as well recurrence, metastatic, disease-free survival (DFS) as overall (OS) rates of patients with JI-GIST or gastric GIST (G-GIST) were collected and compared.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Any kind of primary mesenchymal tumor of the gastrointestinal tract with a histomorphological and immunohistochemical (CD117 (+) and/or DOG1 (+)) profile consistent with GIST.

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
KIT Gene mutation	15 years	Number of patients with a molecular analysis positive for KIT mutation
PDGFRA Gene mutation	15 years	Number of patients with a molecular analysis positive for PDGFRA mutation
Expression of CD117	15 years	Number of patients with immunohistochemical expression of CD117
Expression of DOG1	15 years	Number of patients with immunohistochemical expression of DOG1
Recurrence	15 years	Number of patients with recurrence after treatment with tyrosinkin inhibitors.
Deceased	15 years	Number of patients deceased during follow-up.
Location	15 years	Location of the tumor (gastric o jejunoileal)

Countries

Spain

Outcome results